Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Alpaparm | Milana 2022 | H Bi-Georgia | Prime line | Ermed Georgia |
|---|---|---|---|---|---|
| Total Revenue | 2,960 | 2,943 | 2,844 | 2,814 | — |
| Total COGS | -1,348 | -1,154 | -854 | -1,269 | — |
| Gross Profit | 1,612 | 1,789 | 1,990 | 1,545 | — |
| Gross Margin | 54.5% | 60.8% | 70.0% | 54.9% | — |
| Total Operating Expenses | -594 | -130 | -854 | -961 | — |
| EBITDA | 1,018 | 1,658 | 1,136 | 584 | — |
| EBITDA Margin | 34.4% | 56.4% | 39.9% | 20.8% | — |
| Total D&A | -5 | 0 | -6 | -83 | — |
| EBIT / Operating Income | 1,013 | 1,658 | 1,130 | 502 | — |
| Total Interest Income | 11 | 1 | — | — | — |
| Total Other Income | 89 | 102 | -117 | 255 | — |
| Profit Before Tax | 1,112 | 1,761 | 1,013 | 731 | — |
| Total Income Tax | -254 | 0 | 0 | -37 | — |
| Net Profit / (Loss) | 858 | 1,761 | 1,013 | 527 | — |
| Net Margin | 29.0% | 59.8% | 35.6% | 18.7% | — |
| Total Interest Expense | — | — | — | -26 | — |
Not every picked company reports every selected year — FY2024: no filing for Ermed Georgia. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Milana 2022 | Pharma | 56.4% | 99th pct | 110 |
| H Bi-Georgia | Pharma | 39.9% | 91st pct | 110 |
| Alpaparm | Pharma | 34.4% | 84th pct | 110 |
| Prime line | Pharma | 20.8% | 61st pct | 110 |
| Ermed Georgia | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.